Frontlight ResearchEarly access
SuspendedPhase 2
A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity
Key facts
- Who runs it
- University of California, San Diego
- Where
- San Diego, United StatesSee the site
- Trial code
- Status
- Suspended
- Phase
- Phase 2
- People taking part
- 21 people enrolled
- Started
- Dec 2007
- Expected to end
- Jan 2099
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Fenretinide
- Placebo
- Record updated
- 10 February 2021
- Why it stopped
- This study was terminated due to expired drug with possibility of re-starting in the future.
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- BMI >30
Who cannot take part
- Diabetes Requiring Medication
- Poorly Controlled Co-Morbidities
Where in United States
- University of California at San Diego HospitalsSan Diego, United States
About the trial
What the trial wants to find out
Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.
The 2 groups in the trial
- ATreatment being tested
Subjects in this cohort will be given Fenretinide
Treatment: Fenretinide
- BPlacebo, for comparison
Subjects in this cohort will be given placebo.
Treatment: Placebo
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 2 Study of the Assessment of the Insulin Sensitizing Activity of Fenretinide in Subjects With Insulin Resistance With BMI >30Kg/m2, and Liver Inflammation Related to Non-alcoholic Fatty Liver
- Record updated
- 10 February 2021